Amphastar Pharmaceuticals, Inc. (AMPH)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 70M 140M 210M Q1 '13: 53M Q2 '13: 62.5M Q3 '13: 59.3M Q4 '13: 54.9M Q1 '14: 45.9M Q2 '14: 49M Q3 '14: 59.7M Q4 '14: 55.9M Q1 '15: 56.9M Q2 '15: 53.9M Q3 '15: 63.9M Q4 '15: 76.9M Q1 '16: 59.4M Q2 '16: 68M Q3 '16: 64.2M Q4 '16: 63.5M Q1 '17: 56.7M Q2 '17: 65.2M Q3 '17: 57.9M Q4 '17: 60.4M Q1 '18: 58.4M Q2 '18: 71M Q3 '18: 75.5M Q4 '18: 89.7M Q1 '19: 79.8M Q2 '19: 79M Q3 '19: 80.1M Q4 '19: 83.4M Q1 '20: 84.7M Q2 '20: 85.8M Q3 '20: 83.4M Q4 '20: 95.9M Q1 '21: 103M Q2 '21: 101.7M Q3 '21: 112.2M Q4 '21: 120.9M Q1 '22: 120.4M Q2 '22: 123.5M Q3 '22: 120.1M Q4 '22: 135M Q1 '23: 140M Q2 '23: 145.7M Q3 '23: 180.6M Q4 '23: 178.1M Q1 '24: 171.8M Q2 '24: 182.4M Q3 '24: 191.2M Q4 '24: 186.5M Q1 '25: 170.5M Q2 '25: 174.4M Q3 '25: 191.8M Q4 '25: 183.1M Q1 '26: 171.2M Q2 '26: 183.9M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Gross Profit Quarterly

0 40M 80M 120M Q1 '13: 19.6M Q2 '13: 27.5M Q3 '13: 20.3M Q4 '13: 19.6M Q1 '14: 12.5M Q2 '14: 15M Q3 '14: 11.8M Q4 '14: 12M Q1 '15: 13.3M Q2 '15: 13.3M Q3 '15: 17.6M Q4 '15: 33.2M Q1 '16: 24.9M Q2 '16: 31.7M Q3 '16: 27.6M Q4 '16: 20M Q1 '17: 22.8M Q2 '17: 26.7M Q3 '17: 20.6M Q4 '17: 20.5M Q1 '18: 17M Q2 '18: 26.1M Q3 '18: 29.3M Q4 '18: 34.7M Q1 '19: 30.9M Q2 '19: 32.4M Q3 '19: 35.3M Q4 '19: 33.4M Q1 '20: 36.8M Q2 '20: 33.2M Q3 '20: 36.5M Q4 '20: 36.8M Q1 '21: 44.9M Q2 '21: 47.4M Q3 '21: 51.2M Q4 '21: 56.2M Q1 '22: 55.8M Q2 '22: 63.4M Q3 '22: 58.5M Q4 '22: 71.2M Q1 '23: 73.8M Q2 '23: 72.7M Q3 '23: 108.4M Q4 '23: 96.1M Q1 '24: 90.1M Q2 '24: 95.2M Q3 '24: 101.9M Q4 '24: 86.6M Q1 '25: 85.3M Q2 '25: 86.5M Q3 '25: 98.6M Q4 '25: 85.7M Q1 '26: 70.3M Q2 '26: 93.5M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Operating Income Quarterly

-25M 0 25M 50M 75M Q1 '13: 2.4M Q2 '13: 12M Q3 '13: 226K Q4 '13: 2.9M Q1 '14: -2M Q2 '14: -1.2M Q3 '14: -7.8M Q4 '14: -7M Q1 '15: -7.3M Q2 '15: -10.3M Q3 '15: -3.7M Q4 '15: 14.4M Q1 '16: 4.1M Q2 '16: 10.3M Q3 '16: 5.8M Q1 '17: 1.4M Q2 '17: 2.2M Q3 '17: -2.9M Q4 '17: -1.9M Q1 '18: -9.8M Q2 '18: -2.9M Q3 '18: 2.5M Q4 '18: 1.5M Q1 '19: -3.2M Q2 '19: 973K Q3 '19: 2.4M Q4 '19: -244K Q1 '20: 7.5M Q2 '20: -2.9M Q3 '20: 3.5M Q4 '20: 2.9M Q1 '21: 10.3M Q2 '21: 10.6M Q3 '21: 24.8M Q4 '21: 24.3M Q1 '22: 21.6M Q2 '22: 24.8M Q3 '22: 23.2M Q4 '22: 37.8M Q1 '23: 33.4M Q2 '23: 36.9M Q3 '23: 72.7M Q4 '23: 54M Q1 '24: 48M Q2 '24: 55.2M Q3 '24: 57M Q4 '24: 45.1M Q1 '25: 37.3M Q2 '25: 42.2M Q3 '25: 25.3M Q4 '25: 35.6M Q1 '26: 13.6M Q2 '26: 39.7M Q4 '13 Q3 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Net Income Quarterly

-20M 0 20M 40M 60M Q1 '13: 2.4M Q2 '13: 7.8M Q3 '13: -159K Q4 '13: 1.8M Q1 '14: -1.6M Q2 '14: -1.2M Q3 '14: -5.4M Q4 '14: -2.5M Q1 '15: -665K Q2 '15: -6.6M Q3 '15: -3M Q4 '15: 7.5M Q1 '16: 2.5M Q2 '16: 6.9M Q3 '16: 3.9M Q4 '16: -2.7M Q1 '17: 893K Q2 '17: 2M Q3 '17: 99K Q4 '17: 1.5M Q1 '18: -7.1M Q2 '18: -2.9M Q3 '18: 2.4M Q4 '18: 1.9M Q1 '19: 868K Q2 '19: 47.8M Q3 '19: 1.3M Q4 '19: -1M Q1 '20: 3.9M Q2 '20: -192K Q3 '20: 3.9M Q4 '20: -6.3M Q1 '21: 5M Q2 '21: 7.8M Q3 '21: 29.5M Q4 '21: 19.8M Q1 '22: 24.3M Q2 '22: 17.3M Q3 '22: 15.9M Q4 '22: 33.9M Q1 '23: 26M Q2 '23: 26.1M Q3 '23: 49.2M Q4 '23: 36.2M Q1 '24: 43.2M Q2 '24: 37.9M Q3 '24: 40.4M Q4 '24: 38M Q1 '25: 25.3M Q2 '25: 31M Q3 '25: 17.4M Q4 '25: 24.4M Q1 '26: 6.4M Q2 '26: 30.3M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Cost of Revenue Quarterly

0 35M 70M 105M Q1 '13: 33.4M Q2 '13: 35M Q3 '13: 39M Q4 '13: 35.2M Q1 '14: 33.4M Q2 '14: 34M Q3 '14: 47.9M Q4 '14: 43.9M Q1 '15: 43.6M Q2 '15: 40.5M Q3 '15: 46.3M Q4 '15: 43.7M Q1 '16: 34.5M Q2 '16: 36.3M Q3 '16: 36.6M Q4 '16: 43.6M Q1 '17: 33.8M Q2 '17: 38.4M Q3 '17: 37.4M Q4 '17: 39.9M Q1 '18: 41.4M Q2 '18: 45M Q3 '18: 46.3M Q4 '18: 55M Q1 '19: 48.9M Q2 '19: 46.7M Q3 '19: 44.9M Q4 '19: 50M Q1 '20: 47.9M Q2 '20: 52.6M Q3 '20: 46.9M Q4 '20: 59.1M Q1 '21: 58.1M Q2 '21: 54.3M Q3 '21: 61M Q4 '21: 64.7M Q1 '22: 64.5M Q2 '22: 60.1M Q3 '22: 61.6M Q4 '22: 63.9M Q1 '23: 66.2M Q2 '23: 73M Q3 '23: 72.2M Q4 '23: 82M Q1 '24: 81.7M Q2 '24: 87.2M Q3 '24: 89.3M Q4 '24: 99.9M Q1 '25: 85.3M Q2 '25: 87.9M Q3 '25: 93.2M Q4 '25: 97.4M Q1 '26: 100.8M Q2 '26: 90.4M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Operating Cash Flow Quarterly

-25M 0 25M 50M 75M Q3 '13: 709K Q4 '13: 8.5M Q1 '14: -5.8M Q2 '14: 934K Q3 '14: 13.6M Q4 '14: 12.3M Q1 '15: 1.3M Q2 '15: 2.5M Q3 '15: 3.6M Q4 '15: 3.3M Q1 '16: 13.9M Q2 '16: 9.3M Q3 '16: 1.3M Q4 '16: 14M Q1 '17: 22.4M Q2 '17: 4.6M Q3 '17: 2.5M Q4 '17: 9.8M Q1 '18: 8.4M Q2 '18: 4.5M Q3 '18: 15.8M Q4 '18: 9.5M Q1 '19: -3.6M Q2 '19: 51.7M Q3 '19: -12M Q4 '19: 5.7M Q1 '20: 1.5M Q2 '20: 30.1M Q3 '20: 8.8M Q4 '20: 16.9M Q1 '21: 22.8M Q2 '21: 32.2M Q3 '21: 2.6M Q4 '21: 40.4M Q1 '22: 50.8M Q2 '22: 2.8M Q3 '22: 20.4M Q4 '22: 15.2M Q1 '23: 40.4M Q2 '23: 54.9M Q3 '23: 64.3M Q4 '23: 23.9M Q1 '24: 55.3M Q2 '24: 69.1M Q3 '24: 60M Q4 '24: 29M Q1 '25: 35.1M Q2 '25: 35.6M Q3 '25: 52.6M Q4 '25: 32.9M Q1 '26: 47.8M Q2 '26: 51.3M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Free Cash Flow Quarterly

-25M 0 25M 50M 75M Q3 '13: -3.6M Q4 '13: 4.8M Q1 '14: -9.9M Q2 '14: -2.1M Q3 '14: 9.6M Q4 '14: 2.9M Q1 '15: -2.4M Q2 '15: -457K Q3 '15: -392K Q4 '15: -2M Q1 '16: 10M Q2 '16: 3.9M Q3 '16: -5.4M Q4 '16: 8.7M Q1 '17: 15.1M Q2 '17: -1.7M Q3 '17: -8.9M Q4 '17: -353K Q1 '18: -4M Q2 '18: -7.7M Q3 '18: 3.1M Q4 '18: -65K Q1 '19: -18.4M Q2 '19: 42M Q3 '19: -20.7M Q4 '19: -2.8M Q1 '20: -6.5M Q2 '20: 19.2M Q3 '20: 3.2M Q4 '20: 7.6M Q1 '21: 15.2M Q2 '21: 26.4M Q3 '21: -4.7M Q4 '21: 33.6M Q1 '22: 44.6M Q2 '22: -3.1M Q3 '22: 14.8M Q4 '22: 8.9M Q1 '23: 30.9M Q2 '23: 45.9M Q3 '23: 54.1M Q4 '23: 14.4M Q1 '24: 46.5M Q2 '24: 63.1M Q3 '24: 46.2M Q4 '24: 16.6M Q1 '25: 24.4M Q2 '25: 25M Q3 '25: 47.2M Q4 '25: 24.6M Q1 '26: 38.3M Q2 '26: 42.7M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q1 '13: 38.8M Q2 '13: 38.8M Q3 '13: 38.7M Q4 '13: 39.1M Q1 '14: 38.8M Q2 '14: 39.8M Q3 '14: 44.6M Q4 '14: 44.6K Q1 '15: 44.6M Q2 '15: 44.8M Q3 '15: 45.3M Q4 '15: 46.7M Q1 '16: 46.8M Q2 '16: 46M Q3 '16: 48M Q4 '16: 46.1M Q1 '17: 48.1M Q2 '17: 47.9M Q3 '17: 48.2M Q4 '17: 49.3M Q1 '18: 46.5M Q2 '18: 46.6M Q3 '18: 48.3M Q4 '18: 49.2M Q1 '19: 50.4M Q2 '19: 49.9M Q3 '19: 50.1M Q4 '19: 46.8M Q1 '20: 48.2M Q2 '20: 46.8M Q3 '20: 49.8M Q1 '21: 49.5M Q2 '21: 49.6M Q3 '21: 50M Q1 '22: 52M Q2 '22: 53.2M Q3 '22: 52.8M Q1 '23: 52M Q2 '23: 53.1M Q3 '23: 53.9M Q1 '24: 53M Q2 '24: 52M Q3 '24: 51.9M Q1 '25: 49.9M Q2 '25: 48.1M Q3 '25: 47.7M Q1 '26: 46.5M Q2 '26: 44.2M Q2 '14 Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.50 0.00 1.50 3.00 4.50 Q4 '13: 0.31 Q1 '14: 0.21 Q2 '14: -0.02 Q3 '14: -0.14 Q4 '15: -0.07 Q1 '16: -0.01 Q2 '16: 0.29 Q3 '16: 0.44 Q4 '16: 0.22 Q1 '17: 0.19 Q2 '17: 0.08 Q3 '17: 0.00 Q4 '17: 0.08 Q1 '18: -0.09 Q2 '18: -0.19 Q3 '18: -0.14 Q4 '18: -0.12 Q1 '19: 0.05 Q2 '19: 1.07 Q3 '19: 1.05 Q4 '19: 0.99 Q1 '20: 1.05 Q2 '20: 0.09 Q3 '20: 0.14 Q4 '20: 0.03 Q1 '21: 0.05 Q2 '21: 0.21 Q3 '21: 0.72 Q4 '21: 1.25 Q1 '22: 1.62 Q2 '22: 1.79 Q3 '22: 1.50 Q4 '22: 1.75 Q1 '23: 1.78 Q2 '23: 1.94 Q3 '23: 2.55 Q4 '23: 2.59 Q1 '24: 2.90 Q2 '24: 3.14 Q3 '24: 3.01 Q4 '24: 3.06 Q1 '25: 2.76 Q2 '25: 2.67 Q3 '25: 2.26 Q4 '25: 2.03 Q1 '26: 1.66 Q2 '26: 1.69 Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.